Research on the cell biology of tumors. Covers cancer-cell vulnerabilities, tumor spread, nanoreactor therapies, and AI-guided cancer research.
Researchers developed nanostraws that can sample a single cell at a time without damaging it, allowing for long-term non-destructive monitoring of cellular processes. This technique could inform cancer treatments and help develop patient-specific organs by understanding how stem cells evolve.
Researchers used super-resolution imaging to map the organization of cadherin-based adhesions in cells. The study revealed a multi-layered structure with compartments separated by an interface layer containing vinculin, which plays a key role in fine-tuning mechanical properties.
Researchers have witnessed Organo-Osmium FY26 targeting and destroying cancer cells from the inside by attacking their weakest part. The compound is 50x more active than current cancer drugs like cisplatin.
Researchers at MIT have developed a new portable technology called Seq-Well, which enables rapid analysis of large numbers of cells for single-cell RNA sequencing. This breakthrough allows scientists to easily identify different cell types found in tissue samples, facilitating the study of immune cell responses and cancer treatment.
Telomeres are protective caps on chromosomes that protect DNA ends from damage. Brian Luke's research focuses on the non-coding RNA TERRA, which plays a crucial role in telomere function. His lab will also investigate telomere looping, a mechanism that protects chromosome ends from degradation.
Researchers at OIST have developed a novel technique that targets lipid rafts on cancer cell membranes to block migration. The molecule works by physically pinning the cancer cell, causing it to rupture and leading to cell death.
IFT20 protein plays a crucial role in the formation of invadopodia, structures that enable tumor cells to break through barriers and infiltrate surrounding tissues. The discovery sheds light on the molecular mechanism underlying cancer cell invasion.
A new mathematical model reveals that metronomic chemotherapy's benefits rely on the normalization of tumor blood vessels, improving drug delivery and immune cell activity. The approach aims to alleviate abnormal tumor blood vessel structure and function, reducing proliferation of stem-like cancer cells.
Researchers from the University of Jena investigate the effects of five types of nuts on colon cancer cells, finding that they activate the body's defences to detoxify reactive oxygen species. Nuts stimulate the activity of protective enzymes catalase and superoxide dismutase, inducing programmed cell death in cancer cells.
Researchers at Whitehead Institute have identified essential genes in human cancer cells, revealing potential vulnerabilities for new therapies. By analyzing genetic interactions, they discovered a genetically defined subset of cancers that could be exploited with existing treatments.
Researchers discovered LSD binds at an angle, trapping it in the receptor, and part of the protein folds over, sealing it inside. This explains why LSD trips last for a full day despite small doses.
Researchers define how anti-cancer molecules work, binding to microtubules and destabilizing cell growth. The study's findings can be used to optimize and develop new, safer drugs.
Researchers at the University of Illinois used a novel imaging technique to visualize microscopic shifts in metabolism and vesicle production in tumor cells. The study found that these changes can precede larger-scale events in the tumor environment, potentially preparing the way for cancerous cells to spread and metastasize.
A new screening method combining CRISPR genome editing with single-cell RNA sequencing enables the simultaneous analysis of thousands of genes in individual cells. This approach, called CROP-seq, allows researchers to study complex biological mechanisms and identify novel drug targets more efficiently than traditional methods.
Cholesterol is found predominantly in the outer layer of cell membranes, where it transmits signals across the membrane. In cancer cells, high levels of cholesterol are associated with suppressed growth activity, suggesting a new way to treat cancer through pharmacological modulation.
Researchers have found a protein called BCL-2 crucial in controlling the reservoir of NK cells, which may be vulnerable to new medicines that inhibit it. Boosting NK cell numbers with IL-15 could offer a valuable approach to boosting immunity against viral infections or cancer.
Researchers at Kumamoto University find that interleukin-6 (IL-6) helps cancer cells survive radiation therapy by suppressing oxidative stress through the Nrf2-antioxidant pathway. This discovery offers new potential therapies targeting IL-6 to combat radioresistant cancers.
Researchers found that cells with an extra chromosome grew more slowly and formed smaller tumors than comparable cells with normal chromosome number. However, after weeks of growth, these cells rapidly evolved to acquire new mutations that enabled them to grow rapidly.
Researchers at TSRI have discovered a protein called TZAP that regulates telomere length, which is crucial for determining cell lifespan and preventing cancer. Understanding this process opens up new avenues for studying aging and developing treatments.
Researchers from Goethe University Frankfurt discovered a novel biomarker, SAMHD1, that enables accurate prediction of therapy responders and non-responders in acute myeloid leukaemia (AML) patients. This biomarker can guide cytarabine-based chemotherapies to only those patients likely to respond, sparing others from toxic side effects.
Two studies reveal that cancer cells can tolerate genetic mutations by inactivating the BCL9L gene and slowing down division to avoid mistakes, allowing them to thrive and evolve. This understanding may lead to new ways to target cancer cells and improve treatment efficacy.
Scientists have discovered a unique 'gear' in the molecular motor protein KlpA that enables it to switch direction of movement, allowing chromosomes to be properly divided during cell division. This finding could lead to novel treatments for certain types of cancers.
Researchers aim to remove senescent cells, which accumulate with age, to regrow hair, improve organ function and combat aging. However, hurdles include safety issues, off-target effects and high costs, limiting translation to humans.
A combination of metformin and syrosingopine drives cancer cells to programmed 'suicide' by blocking their energy supply, inhibiting growth and inducing tumor cell death. The treatment shows promise for targeting the energy needs of tumor cells.
A study published in Nature discovered that fat utilization is required for the development and growth of lymphatic vessels, a key route for cancer cell spread. Researchers found that inhibiting fat usage can control lymphatic vessel growth, offering new avenues for preventing metastasis and treating complications like lymphedema.
Researchers discovered an obesity-linked protein FTO's role in leukemia cell growth, survival, and drug response. FTO modulates gene expression by altering RNA modification, leading to cancer-promoting effects.
Scientists from the Niels Bohr Institute have identified a new way to control the production of important proteins that regulate the immune system. The discovery could provide a new opportunity to fight diseases such as cancer, Alzheimer's, and diabetes by controlling the cell's genetic response.
A protein called Peroxiredoxin 1 (PRDX1) has been identified as a key player in protecting telomeres from oxidative damage. By analyzing the protein composition of telomeres across the cell cycle, researchers found that PRDX1 functions as an antioxidant enzyme, preserving telomeric DNA for extension by telomerase.
Researchers found that a high-fat, low-sugar diet for 72 hours prior to diagnostic imaging improved the accuracy of diagnosing cardiac sarcoidosis. This technique minimizes indeterminate findings and allows clinicians to better monitor patient progress under treatment.
Researchers at the Salk Institute have discovered that intermittent expression of genes normally associated with an embryonic state can reverse the hallmarks of old age. This approach resulted in the rejuvenation of mice with a premature aging disease, countering signs of aging and increasing their lifespan by 30%. The early-stage work...
A team of scientists from Helmholtz Zentrum München has isolated and characterized therapy-resistant leukemia cells, which are responsible for relapse in the disease. These cells can be eliminated using modern genetic engineering techniques, offering a new approach to prevent disease relapse.
Researchers found that KRAS mutant cancer cells form more stress granules in response to chemotherapy, making them harder to kill. A new compound target, 15-d-PGJ2, may help improve treatment outcomes by blocking this coping mechanism.
Researchers have developed a new technique to switch key biomolecules on and off, allowing them to study the effects of kinases as they work in living cells. This breakthrough could lead to the discovery of novel drug targets for cancer treatment.
Researchers at Ulsan National Institute of Science and Technology (UNIST) have made a groundbreaking discovery in cancer treatment. They developed novel Iridium(III) complexes that utilize red light to attack and kill cancer cells, providing a promising new approach for photodynamic therapy (PDT).
Researchers at La Jolla Institute for Immunology found that the loss of TET proteins hinders T cell maturation and promotes aberrant proliferation, leading to a lethal disease resembling lymphoma. The study's findings suggest that TET proteins serve as tumor suppressors and may help block malignancy in cancers marked by TET mutations.
Researchers at UT Southwestern Medical Center found that intermittent fasting inhibits the development and progression of acute lymphoblastic leukemia (ALL), a type of childhood leukemia. However, fasting was ineffective against another type of blood cancer commonly affecting adults, acute myeloid leukemia (AML).
Researchers have made a major discovery about how cells control when to divide, revealing a key part of the cellular machinery that prevents cells from dividing until DNA is properly aligned. This finding could lead to new treatments for cancer by forcing cancer cells into premature division and killing them.
Scientists have discovered a new class of compounds that can be used to target cancer cells with greater specificity. The technology uses naturally occurring enzymes to trigger the release of therapeutic payloads only at cancer sites.
Researchers have identified a new adaptor protein on the microtubule roadway that helps motors navigate proteins to their correct destinations. This discovery challenges previous assumptions about motor function and has implications for understanding diseases such as cancer and cardiac disease.
Researchers developed an artificial structure that can switch on immune cells to target and destroy cancer cells. The system mimics the cell membrane of antigen-presenting cells, which are responsible for activating immune responses against cancer.
The study found that KTE-C19 induced a significant response rate in patients with diffuse large B-cell lymphoma, with 76% overall response and 47% complete remission. Serious adverse events were reported, but the team developed guidelines to manage side effects across multiple institutions.
The latest ASCB celldance videos offer an immersive look at living cells through powerful imaging technologies. The three selected labs showcased their research using innovative storytelling methods, including spoken word and animation. The videos provide a glimpse into the intricate cellular dance of life.
A group of 12 high-risk acute myeloid leukemia patients who received genetically engineered immune cells are still in remission after over two years. The treatment was successful in recognizing and destroying cancer cells, with no relapse observed in this cohort.
A metabolite called D-2-hydroxyglutarate (D-2HG) has been identified as a promising target for future cancer therapies due to its ability to promote cancer cell transformation and increase the likelihood of tumor spread in colorectal cancer patients.
The discovery of EphA2 as a receptor for progranulin sheds light on its role in cancer and neurodegenerative diseases. Progranulin binding activates cellular pathways that promote cancer cell aggression, while also triggering a positive feedback loop that increases progranulin secretion.
Researchers identified a molecule called AXL which triggers the spread of an aggressive form of ovarian cancer. Blocking AXL may be an effective treatment option for patients with Mes subtype ovarian cancer.
Researchers at the University of York and Texas have identified a protein, PAQR11, in the Golgi apparatus that receives a signal from Zeb1, triggering the transport of membrane sacks and altering the cancer cell's perimeter. This process allows cancer cells to detach from their fixed position and travel to other parts of the body.
Researchers at the University of Southampton have engineered human cells with a genetic circuit that produces a molecule inhibiting HIF-1, allowing cancer cells to survive in nutrient-limited environments. The study demonstrates the potential for using sentinel circuits to target diseases like cancer.
A study published in Nature Cell Biology reveals a pro-growth signaling pathway common to many cancers that can be targeted with precision, leading to the efficient killing of cancer cells while leaving healthy cells unaffected. The researchers identified a scaffolding protein IQGAP1 as a key player in this pathway.
Researchers capture elusive DNA reaction intermediates in living cells, discovering mechanisms underlying genome instability and a new role for an E. coli protein related to human cancer proteins. This breakthrough could lead to the development of new drugs that prevent cancer by neutralizing these key pieces of genetic code.
Arecoline, an analog of nicotine, has been identified as an inhibitor of the enzyme ACAT1, which contributes to the Warburg effect in cancer cells. Researchers found that arecoline steers cells' metabolism away from glycolysis, inhibiting growth in human lung cancer and leukemia cells.
Restoring dysfunctional blood vessels in tumors can prevent cancer cells from spreading and improve chemotherapy delivery. Healthy tumor vessels also enhance the supply of immune cells, which is crucial for emerging immunotherapy treatments.
Scientists have established comprehensive maps of the human epigenome, revealing how genes are active in specific cells. The maps, published by the International Human Epigenome Consortium, provide insights into cellular differentiation and potential new treatments for diseases.
A new study by TSRI researchers suggests that disruptions in circadian rhythms may leave levels of an important cancer-linked protein, called cMYC, unchecked. This connection has significant implications for the link between daily rhythms and cell growth.
A study by the University of Leeds found that Reovirus, a common childhood cough virus, can stimulate the body's immune system to kill off liver cancer cells and the hepatitis C virus. The researchers hope to start clinical trials to test its effectiveness in treating primary liver cancer.
Researchers have developed a new cancer treatment called photoimmunotherapy that combines the immune system with laser energy to target and destroy cancer cells. This innovative technique delivers precise, lethal payloads with minimal collateral damage.
A multidisciplinary international team of scientists solved the mystery of ferroptosis, a type of controlled cell death that uses iron to safely destroy and recycle malfunctioning cells. The study aims to develop potential therapies for conditions like radiation injury, cancer and radiation-induced cellular damage.
Researchers at CHLA are developing a new treatment approach for patients with relapsed acute lymphoblastic leukemia (ALL) by targeting the molecule integrin alpha4, which shelters leukemia cells from chemotherapy. The goal is to develop a novel inhibitor of this molecule for clinical use.
A new 'sponge on a string' pill test has been shown to accurately identify people with Barrett's oesophagus who are at low risk of developing oesophageal cancer. This non-invasive test may replace uncomfortable endoscopies for some patients, allowing them to be monitored instead.
Researchers at the University of Pittsburgh Cancer Institute discovered that cancer cells exploit a previously unknown mechanism called alternative lengthening of telomeres (ALT) to reset their telomere clocks. This allows them to continue dividing and growing, making them more aggressive and resistant to treatment.